LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

8 result(s)
Filter and sort
8 result(s)
Journal Article > ResearchFull Text

A standardised phase III clinical trial framework to assess therapeutic interventions for Lassa fever

PLoS Negl Trop Dis. 6 January 2022; Volume 16 (Issue 1); E0010089.; DOI:10.1371/journal.pntd.0010089
Olayinka A, Bourner J, Akpede GO, Okoeguale J, Abejegah C,  et al.
PLoS Negl Trop Dis. 6 January 2022; Volume 16 (Issue 1); E0010089.; DOI:10.1371/journal.pntd.0010089
BACKGROUND
Only one recommendation currently exists for the treatment of Lassa fever (LF), which is ribavirin administered in conjunction with supportive care. This recommendation is primarily based on evidence generated from a single clinical trial that was conducted more than 30 years ago-the methodology and results of which have recently come under scrutiny. The requirement for novel therapeutics and reassessment of ribavirin is therefore urgent. However, a significant amount of work now needs to be undertaken to ensure that future trials for LF can be conducted consistently and reliably to facilitate the efficient generation of evidence.

METHODOLOGY
We convened a consultation group to establish the position of clinicians and researchers on the core components of future trials. A Core Eligibility Criteria (CEC), Core Case Definition (CCD), Core Outcome Set (COS) and Core Data Variables (CDV) were developed through the process of a multi-stakeholder consultation that took place using a modified-Delphi methodology.

RESULTS
A consensus position was achieved for each aspect of the framework, which accounts for the inclusion of pregnant women and children in future LF clinical trials. The framework consists of 8 core criteria, as well as additional considerations for trial protocols.

CONCLUSIONS
This project represents the first step towards delineating the clinical development pathway for new Lassa fever therapeutics, following a period of 40 years without advancement. Future planned projects will bolster the work initiated here to continue the advancement of LF clinical research through a regionally-centred, collaborative methodology, with the aim of delineating a clear pathway through which LF clinical trials can progress efficiently and ensure sustainable investments are made in research capacity at a regional level.
More
Journal Article > ResearchFull Text

The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Médecins Sans Frontières (MSF) Ebola Case Management Centre (CMC), Kailahun, Sierra Leone, June -October, 2014

J Infect Dis. 22 May 2015; Volume 212 (Issue 11); DOI:10.1093/infdis/jiv304
Fitzpatrick G, Vogt F, Gbabai O, Decroo T, Keane M,  et al.
J Infect Dis. 22 May 2015; Volume 212 (Issue 11); DOI:10.1093/infdis/jiv304
This paper describes patient characteristics, including Ebola viral load, associated with mortality in an MSF Ebola case management centre. Out of 780 admissions between June and October 2014, 525 (67%) were positive for Ebola with a known outcome. The crude mortality rate was 51% (270/525). Ebola viral load (whole blood sample) data was available on 76% (397/525) of patients. Univariate analysis indicated viral load at admission, age, symptom duration prior to admission and distance travelled to the CMC were associated with mortality (p value<0.05). The multivariable model predicted mortality in those with a viral load at admission greater than 10 million copies per millilitre (p value<0.05, Odds Ratio>10), aged 50 years or more (p value=0.08, Odds Ratio=2) and symptom duration prior to admission less than 5 days (p value=0.14). The presence of confusion, diarrhoea and conjunctivitis were significantly higher (p value<0.05) in Ebola patients who died. These findings highlight the importance viral load at admission has on mortality outcomes and could be used to cohort cases with viral loads greater than 10 million copies into dedicated wards with more intensive medical support to further reduce mortality.More
Journal Article > CommentaryAbstract

New filovirus disease classification and nomenclature

Nat Microbiol. 29 March 2019 (Issue 5)
De Clerck H, Nanclares C, Sprecher A, Van Herp M, Wolz A
Nat Microbiol. 29 March 2019 (Issue 5)
The recent large outbreak of Ebola virus disease (EVD) in Western Africa resulted in greatly increased accumulation of human genotypic, phenotypic and clinical data, and improved our understanding of the spectrum of clinical manifestations. As a result, the WHO disease classification of EVD underwent major revision.More
Journal Article > CommentaryFull Text

Emerging Filoviral Disease in Uganda: Proposed Explanations and Research Directions

Am J Trop Med Hyg. 10 February 2014; Volume 90 (Issue 5); DOI:10.4269/ajtmh.13-0374
Polonsky JA, Wamala JF, De Clerck H, Van Herp M, Sprecher A,  et al.
Am J Trop Med Hyg. 10 February 2014; Volume 90 (Issue 5); DOI:10.4269/ajtmh.13-0374
Outbreaks of Ebola and Marburg virus diseases have recently increased in frequency in Uganda. This increase is probably caused by a combination of improved surveillance and laboratory capacity, increased contact between humans and the natural reservoir of the viruses, and fluctuations in viral load and prevalence in this reservoir. The roles of these proposed explanations must be investigated to guide appropriate responses to the changing epidemiological profile. Other African settings in which multiple filoviral outbreaks have occurred could also benefit from such information.More
Journal Article > ResearchFull Text

Unique human immune signature of Ebola Virus Disease in Guinea

Nature. 4 May 2016; Volume 533 (Issue 7601); 100-104.; DOI:10.1038/nature17949
Ruibal P, Oestereich L, Ludtke A, Becker-Ziaja B, Wozniak DM,  et al.
Nature. 4 May 2016; Volume 533 (Issue 7601); 100-104.; DOI:10.1038/nature17949
Despite the magnitude of the Ebola virus disease (EVD) outbreak in West Africa, there is still a fundamental lack of knowledge about the pathophysiology of EVD. In particular, very little is known about human immune responses to Ebola virus. Here we evaluate the physiology of the human T cell immune response in EVD patients at the time of admission to the Ebola Treatment Center in Guinea, and longitudinally until discharge or death. Through the use of multiparametric flow cytometry established by the European Mobile Laboratory in the field, we identify an immune signature that is unique in EVD fatalities. Fatal EVD was characterized by a high percentage of CD4(+) and CD8(+) T cells expressing the inhibitory molecules CTLA-4 and PD-1, which correlated with elevated inflammatory markers and high virus load. Conversely, surviving individuals showed significantly lower expression of CTLA-4 and PD-1 as well as lower inflammation, despite comparable overall T cell activation. Concomitant with virus clearance, survivors mounted a robust Ebola-virus-specific T cell response. Our findings suggest that dysregulation of the T cell response is a key component of EVD pathophysiology.More
Conference Material > Poster

Outbreak of ESBL Klebsiella pneumoniae in a maternity unit in Central African Republic

Gil Cuesta J, Thallinger M, Antierens A, Caluwaerts A, Chaillet P,  et al.
MSF Scientific Days International 2018: Research. 14 May 2018; DOI:10.7490/f1000research.1115454.1
Journal Article > ResearchFull Text

Field evaluation of capillary blood samples as a collection specimen for the rapid diagnosis of Ebola virus infection during an outbreak emergency

Clin Infect Dis. 19 May 2015 (Issue 5)
Strecker T, Palyi B, Ellerbrok H, Jonckheere S, De Clerck H,  et al.
Clin Infect Dis. 19 May 2015 (Issue 5)
Reliable reverse-transcriptase polymerase chain reaction (RT-PCR)-based diagnosis of Ebola virus infection currently requires a blood sample obtained by intravenous puncture. During the current Ebola outbreak in Guinea, we evaluated the usability of capillary blood samples collected from fingersticks of patients suspected of having Ebola virus disease (EVD) for field diagnostics during an outbreak emergency.More
Journal Article > Short ReportFull Text

First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease

J Infect Dis. 15 January 2017; DOI:10.1093/infdis/jiw493
Dornemann J, Burzio C, Ronsse A, Sprecher A, De Clerck H,  et al.
J Infect Dis. 15 January 2017; DOI:10.1093/infdis/jiw493
A neonate born to an Ebola virus-positive woman was diagnosed with Ebola virus infection on her first day of life. The patient was treated with monoclonal antibodies (ZMapp), a buffy coat transfusion from an Ebola survivor, and the broad-spectrum antiviral GS-5734. On day 20, a venous blood specimen tested negative for Ebola virus by quantitative reverse-transcription polymerase chain reaction. The patient was discharged in good health on day 33 of life. Further follow-up consultations showed age-appropriate weight gain and neurodevelopment at the age of 12 months. This patient is the first neonate documented to have survived congenital infection with Ebola virus.More